Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1

Inflammatory Bowel Diseases

Volumn 10, Issue 2, 2004, Pages 122-128

  Menzel, Thomas ^a,c   Lührs, Hardi ^a   Zirlik, Sabine ^a   Schauber, Jürgen ^a   Kudlich, Theodor ^a   Gerke, Tobias ^a   Gostner, Andrea ^a   Neumann, Manfred ^b   Melcher, Ralf ^a   Scheppach, Wolfgang ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Anti inflammatory effects; Butyrate; Human endothelial cells; Inflammatory bowel disease (IBD); Nuclear factor kappaB (NF B); Short chain fatty acids; Vascular cell adhesion molecule (VCAM)

Indexed keywords

BUTYRIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL ASSAY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MEDICAL ASSESSMENT; MODULATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; ULCERATIVE COLITIS;

BUTYRATES; CELLS, CULTURED; DRUG INTERACTIONS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 12144288656     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200403000-00010     Document Type: Article

References (45)

1. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest. 1997;100: S37-S39.
2. Ohene-Abuakwa Y, Pignatelli M. Adhesion molecules in cancer biology. Adv Exp Med Biol. 2000;465:115-126.
3. Sans M, Panes J, Ardite E, et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology. 1999;116:874-883.
4. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology. 2001;121:1428-1436.
5. Reyes-Reyes M, Mora N, Gonzalez G, et al. beta1 and beta2 integrins activate different signaling pathways in monocytes. Biochem J. 2002;363: 273-280.
6. Loike JD, Cao L, Budhu S, et al. Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins. J Immunol. 2001;166:7534-7542.
7. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996;2:998-1004.
8. Weber C, Erl W, Pietsch A, et al. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91:1914-1917.
9. Maaser C, Schoeppner S, Kucharzik T, et al. Colonic epithelial cells induce endothelial cell expression of ICAM-1 and VCAM-1 by a NFkappaB-dependent mechanism. Clin Exp Immunol. 2001;124:208-213.
10. Bugaut M. Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals. Comp Biochem Physiol B. 1987; 86:439-472.
11. Archer SY, Meng S, Shei A, et al. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998;95:6791-6796.
12. Emenaker NJ, Basson MD. Short chain fatty acids differentially modulate cellular phenotype and c-myc protein levels in primary human nonmalignant and malignant colonocytes. Dig Dis Sci. 2001;46:96-105.
13. Emenaker NJ, Calaf GM, Cox D, et al. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J Nutr. 2001;131:3041S-3046S.
14. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 2000;60:4561-4572.
15. Mariadason JM, Velcich A, Wilson AJ, et al. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology. 2001;120:889-899.
16. Palmer DG, Paraskeva C, Williams AC. Modulation of p53 expression in cultured colonic adenoma cell lines by the naturally occurring lumenal factors butyrate and deoxycholate. Int J Cancer. 1997;73:702-706.
17. Hague A, Elder DJ, Hicks DJ, et al. Apoptosis in colorectal tumor cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer. 1995;60:400-406.
18. Hague A, Diaz GD, Hicks DJ, et al. bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis. Int J Cancer. 1997;72:898-905.
19. Siavoshian S, Blottiere HM, Cherbut C, et al. Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT-29 colonic epithelial cells. Biochem Biophys Res Commun. 1997;232:169-172.
20. Menzel T, Schauber J, Kreth F, et al. Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells. Eur J Cancer Prev. 2002;11:271-281.
21. Boffa LC, Lupton JR, Mariani MR, et al. Modulation of colonic epithelial cell Proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res. 1992;52: 5906-5912.
22. Luhrs H, Hock R, Schauber J, et al. Modulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cells. Int J Cancer. 2002;97:567-573.
23. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21:793-798.
24. Roediger WE, Lawson MJ, Radcliffe BC. Nitrite from inflammatory cells - a cancer risk factor in ulcerative colitis? Dis Colon Rectum. 1990; 33:1034-1036.
25. Agarwal VP, Schimmel EM. Diversion colitis: a nutritional deficiency syndrome? Nutr Rev. 1989;47:257-261.
26. Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992; 103:51-56.
27. Vernia P, Cittadini M, Caprilli R, et al. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci. 1995;40:305-307.
28. Senagore AJ, MacKeigan JM, Scheider M, et al. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum. 1992;35:923-927.
29. Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci. 1991;36:185-187.
30. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol. 1994;89: 179-183.
31. Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9: 309-313.
32. Kripke SA, Fox AD, Berman JM, et al. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN J Parenter Enteral Nutr. 1989;13:109-116.
33. Kvietys PR, Granger DN. Effect of volatile fatty acids on blood flow and oxygen uptake by the dog colon. Gastroenterology. 1981;80:962-969.
34. Mortensen FV, Nielsen H, Mulvany MJ, et al. Short chain fatty acids dilate isolated human colonic resistance arteries. Gut. 1990;31:1391-1394.
35. Luhrs H, Gerke T, Boxberger F, et al. Butyrate inhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells. Dig Dis Sci. 2001;46:1968-1973.
36. Luhrs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis. 2001;16:195-201.
37. Inan MS, Rasoulpour RJ, Yin L, et al. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology. 2000;118:724-734.
38. Lawrence T, Gilroy DW, Colville-Nash PR, et al. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med. 2001;7:1291-1297.
39. Lassar AB, Buskin JN, Lockshon D, et al. MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell. 1989;58:823-831.
40. Briegel K, Hentsch B, Pfeuffer I, et al. One base pair change abolishes the T cell-restricted activity of a kB-like proto-enhancer element from the interleukin 2 promoter. Nucleic Acids Res. 1991;19:5929-5936.
41. Xia YF, Liu LP, Zhong CP, et al. NF-kappaB activation for constitutive expression of VCAM-1 and ICAM-1 on B lymphocytes and plasma cells. Biochem Biophys Res Commun. 2001;289:851-856.
42. Mattila P, Majuri ML, Mattila PS, et al. TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation. Scand J Immunol. 1992;36:159-165.
43. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527.
44. Zhang F, Yu W, Hargrove JL, et al. Inhibition of TNF-alpha induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atherosclerosis. 2002;161:381-386.
45. Soriano A, Salas A, Sans M, et al. VCAM-1, but not ICAM-1 or MAd-CAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000;80:1541-1551.